Canakinumab is an interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA). Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass.
- Mechanism
- Curator reviewed · 2 references
In inflammatory diseases involving Cryopyrin-Associated Periodic Syndromes (CAPS), interleukin-1 beta (IL-1β) is excessively activated and drives inflammation. The protein cryopyrin controls the activation of IL-1β, and mutations in cryopyrin's gene, NLRP-3, up-regulate IL-1β activation. Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1α or IL-1 receptor antagonist (IL-1ra).
- Primary indication
- Canakinumab is indicated for the treatment of periodic fever syndromes in specific patient populations.Curator reviewed · 9 structured indications
- Formula / weight
- C6452H9958N1722O2010S42 · 145157.0 Da (deglycosylated)
- First approval
- Canada, 2010 · United States, 2009 · European Union, 2016
- Code names
- ACZ-885 · GNR-086
- Brand names
Resolves to
What you can answer from here — as of September 21, 2025
Which drugs share a target with Canakinumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account